38results about "Depsipeptide ingredients" patented technology

Embodiments of the present invention relate to a novel compound of Formula (I)or stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, for use in treatment of infection caused by Gram-negative bacteria.

The present invention relates to a composition comprising tigolaner and, optionally endoparasiticidal agents, a method for its manufacture and its use as a medicament for controlling parasites. Compositions can include tigolaner and 1,2-isopropylideneglycerol, or the composition can include praziquantel, emodepside a solvent component, and tigolaner. The composition can be used in the treatment and / or prevention of parasite infections in animals.

The present invention relates to a composition comprising tigolaner and, optionally endoparasiticidal agents, a method for its manufacture and its use as a medicament for controlling parasites. Compositions can include tigolaner and 1,2-isopropylideneglycerol, or the composition can include praziquantel, emodepside a solvent component, and tigolaner. The composition can be used in the treatment and / or prevention of parasite infections in animals.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic. In certain instances the immunotherapeutic is a chimeric antigen receptor T cell, an antibody or polypeptide that binds a checkpoint inhibitor, or a vaccine.

Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.

The present invention provides pharmaceutical compositions of teixobactin that are capable of preventing gelation of teixobactin. The pharmaceutical compositions comprise teixobactin and a pegylated phospholipid. The present invention also provides methods of preparing the pharmaceutical compositions of teixobactin and methods of treating a subject using the pharmaceutical compositions of teixobactin.

The present disclosure describes a novel method for decellularizing amphibian extracellular matrix to obtain isolated ECM that is substantially free of cellular and nuclear debris. The method includes washing the amphibian ECM in a solution containing one or more detergents, incubating the ECM with one or more proteases, and incubating the ECM with one or more nucleases. The present disclosure also describes various methods of using the isolated ECM.

Provided are a combination of an inositol phosphorylceramide synthase inhibitor and amphotericin B and use thereof. The use includes preparing a pharmaceutical composition, which includes an inositol phosphorylceramide synthetase inhibitor and amphotericin B or a salt thereof. Inositol phosphorylceramide is an important and conserved component of fungal plasma membranes. In the pharmaceutical composition according to an embodiment of the present disclosure, due to the presence of the inositol phosphorylceramide synthase inhibitor, the interaction between the inositol phosphorylceramide synthase inhibitor and amphotericin B not only enhances the inhibitory ability of the inositol phosphorylceramide synthase inhibitor on the synthesis of inositol phosphorylceramide in Cryptococcus, but also effectively reduces the dosage of amphotericin B and prolongs the half-life of amphotericin B, facilitating to reduce the adverse reactions of amphotericin B. The pharmaceutical composition exhibits superior fungicidal effect and safety compared to the currently used clinical combination of 5-fluorocytosine and amphotericin B.

The present invention relates to the use of compounds in the treatment of autoimmune conditions, in particular in the treatment of rheumatoid arthritis.

The present invention provides a use of beauvericin in manufacturing a medicament for inhibiting angiogenesis, in which the therapeutically effective concentration of beauvericin ranges from 0.1 µM to 5 µM; which can be used for preparation of a medicament for preventing or treating a retinal disorder, or a pharmaceutical composition or combination with an anti-cancer drug for treating a cancer.

The present disclosure describes a novel method for decellularizing amphibian extracellular matrix to obtain an isolated ECM that is substantially free of cellular and nuclear debris. The method includes washing the amphibian ECM in solutions containing one or more surfactants, incubating the ECM with one or more proteases, and incubating the ECM with one or more nucleases. The present disclosure also describes various methods of using the isolated ECM.

The application belongs to the field of natural medicines, and particularly relates to cyclic peptide natural products-xylonic acid peptides and the use thereof in the preparation of anti-parasitic drugs. Specifically, 12 cyclic peptide natural products containing xylonic acid structural units are disclosed, which exhibit different degrees of anti-parasitic activity in biological activity tests and have wide application value.

The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss by modulating the rate of Atoh1 protein degradation to increase levels of Atoh1 protein.

The present invention provides a process and intermediates for producing GIP / GLP1 dual agonist peptides, tilzepatide, or pharmaceutically acceptable salts thereof. [Solution] A process is provided for converting a depsipeptide isomer into a desired peptide, comprising: a. adjusting the pH of the depsipeptide isomer to approximately pH 7 to approximately pH 10; and b. incubating the depsipeptide isomer at pH 7 to pH 10 for at least 1 hour.

A PI3K delta inhibitor or a pharmaceutically acceptable salt thereof for use in treating a hematological malignancy in a subject, the treatment comprising administering to the subject i) the PI3K delta inhibitor or a pharmaceutically acceptable salt thereof, and ii) an HDAC inhibitor or a pharmaceutically acceptable salt thereof, separately, sequentially, or simultaneously. The treatment can also further comprise administering to the subject iii) a further chemotherapeutic agent, separately, sequentially, or simultaneously.

The present invention relates to a combination of lysobacin and an aminoglycoside antibiotic for use in the treatment of diseases caused by Gram-positive and Gram-negative bacteria in non-human animals. The present invention is demonstrated to be particularly suitable for use involving the treatment of mastitis in non-human animals. Especially, bovine mastitis can be well solved by the traditional Chinese medicine.

The application provides application of a ZNF652 gene as a marker in preparation of a kit for evaluating cancer occurrence risk and / or prognosis, wherein the ZNF652 gene as the marker comprises transcription of ZNF652 and / or loss of heterozygosity (LOH) of ZNF652. Further provided is use of a ZNF652 gene expression detection reagent in preparation of a kit for guiding anti-PD-L1 immunotherapy and guiding combination use of an anti-PD-L1 antibody. Further provided is use of an HDAC inhibitor romidepsin combined with an anti-PD-L1 antibody in preparation of a breast cancer treatment drug. The application provides an important theoretical basis for evaluating occurrence risk, treatment and prognosis of clinical triple-negative breast cancer.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic. In certain instances the immunotherapeutic is a chimeric antigen receptor T cell, an antibody or polypeptide that binds a checkpoint inhibitor, or a vaccine.

Provided are compositions that include histone deacetylase (HDAC) inhibitors encapsulated in and / or otherwise associated with detectable nanoparticles, and methods for using the same in medical and veterinary applications including but not limited to treating diseases, disorders, and / or conditions associated with sensitivity to HDAC inhibitors; inhibiting the growth, proliferation, and / or metastasis of a tumor and / or a cancer associated with sensitivity to HDAC inhibitors, and for treating inflammatory and / or an autoimmune diseases, disorders, and / or conditions associated with sensitivity to HDAC inhibitors. Also provided are methods for imaging cells, tissues, organs, and / or other targets in subject.

The present disclosure describes a novel method for decellularizing amphibian extracellular matrix to obtain isolated ECM that is substantially free of cellular and nuclear debris. The method includes washing the amphibian ECM in a solution containing one or more detergents, incubating the ECM with one or more proteases, and incubating the ECM with one or more nucleases. The present disclosure also describes various methods of using the isolated ECM.

The objective of the present invention is to provide a pharmaceutical composition for treating triple-negative breast cancer, which contains actinomycin and doxorubicin as active ingredients. [Solution] The pharmaceutical composition of the present invention can target and bind to a specific nucleic acid sequence due to the synergistic effect of actinomycin and doxorubicin, and therefore can suppress or treat triple-negative breast cancer while reducing the dosage of doxorubicin, and can effectively reduce the side effects of chemotherapy drugs.

The present disclosure describes a novel method for decellularizing amphibian extracellular matrix to obtain an isolated ECM that is substantially free of cellular and nuclear debris. The method includes washing the amphibian ECM in solutions containing one or more surfactants, incubating the ECM with one or more proteases, and incubating the ECM with one or more nucleases. The present disclosure also describes various methods of using the isolated ECM.

A PI3K-delta inhibitor or a pharmaceutically acceptable salt thereof, for use in the treatment of a haematological malignancy in a subject, wherein said treatment comprises the separate, sequential or simultaneous administration of i) said PI3K-delta inhibitor, or a pharmaceutically acceptable salt thereof, and ii) a HDAC inhibitor, or a pharmaceutically acceptable salt thereof, to said subject. The treatment can also further comprise the separate, sequential or simultaneous administration of iii) a further chemotherapeutic agent, to said subject.

The invention belongs to the field of natural medicines, and particularly relates to an anti-parasitic cyclopeptide and application thereof. In particular to 12 cyclic peptide natural products containing xylonic acid structural units, and the cyclic peptide natural products show different degrees of anti-parasitic activity in a biological activity test and have wide application value.

The present invention pertains to a synergistic combination comprising histone deacetylase inhibitors (HDACi) in combination with estrogen receptor (ER) antagonist for treating gliomas. The present invention also discloses composition containing the combination, and a method of use of the combination and the composition of the present invention and method of treatment using the combination.